Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.
Outstanding track record 6 star dividend payer.
Share Price & News
How has Pfizer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PFE has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: PFE underperformed the US Market which returned 17.9% over the past year.
Price Volatility Vs. Market
How volatile is Pfizer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StPfizer (NYSE:PFE) Seems To Use Debt Quite Sensibly
3 weeks ago | Simply Wall StEarnings Miss: Pfizer Inc. Missed EPS By 16% And Analysts Are Revising Their Forecasts
1 month ago | Simply Wall StHow Much Are Pfizer Inc. (NYSE:PFE) Insiders Taking Off The Table?
Is Pfizer undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PFE ($35.72) is trading below our estimate of fair value ($82.32)
Significantly Below Fair Value: PFE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PFE is good value based on its PE Ratio (12.2x) compared to the Pharmaceuticals industry average (21.6x).
PE vs Market: PFE is good value based on its PE Ratio (12.2x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: PFE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: PFE is good value based on its PB Ratio (3x) compared to the US Pharmaceuticals industry average (3x).
How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PFE's earnings are forecast to decline over the next 3 years (-5.6% per year).
Earnings vs Market: PFE's earnings are forecast to decline over the next 3 years (-5.6% per year).
High Growth Earnings: PFE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PFE's revenue (1.5% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: PFE's revenue (1.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (26.1%)
How has Pfizer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PFE has high quality earnings.
Growing Profit Margin: PFE's current net profit margins (31.4%) are higher than last year (20.8%).
Past Earnings Growth Analysis
Earnings Trend: PFE's earnings have grown by 18.6% per year over the past 5 years.
Accelerating Growth: PFE's earnings growth over the past year (46%) exceeds its 5-year average (18.6% per year).
Earnings vs Industry: PFE earnings growth over the past year (46%) exceeded the Pharmaceuticals industry 2.4%.
Return on Equity
High ROE: PFE's Return on Equity (24.9%) is considered high.
Return on Assets
Return on Capital Employed
How is Pfizer's financial position?
Financial Position Analysis
Short Term Liabilities: PFE's short term assets ($33.5B) do not cover its short term liabilities ($37.0B).
Long Term Liabilities: PFE's short term assets ($33.5B) do not cover its long term liabilities ($68.1B).
Debt to Equity History and Analysis
Debt Level: PFE's debt to equity ratio (80.5%) is considered high.
Reducing Debt: PFE's debt to equity ratio has increased from 51.3% to 80.5% over the past 5 years.
Debt Coverage: PFE's debt is well covered by operating cash flow (25.7%).
Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (13.3x coverage).
Inventory Level: PFE has a low level of unsold assets or inventory.
Debt Coverage by Assets: PFE's debt is not covered by short term assets (assets are 0.6x debt).
What is Pfizer's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: PFE's dividend (4.26%) is higher than the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: PFE's dividend (4.26%) is in the top 25% of dividend payers in the US market (3.73%)
Stability and Growth of Payments
Stable Dividend: PFE's dividends per share have been stable in the past 10 years.
Growing Dividend: PFE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (49.3%), PFE's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PFE's dividends in 3 years are forecast to be covered by earnings (50.3% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Albert Bourla (57yo)
Mr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Mr. Bourla was Chief Operating Officer ...
CEO Compensation Analysis
Compensation vs Market: Albert's total compensation ($USD9.85M) is about average for companies of similar size in the US market ($USD10.81M).
Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.
|Chairman of the Board & CEO||1.1yrs||US$9.85m||0.0051% $10.1m|
|Group President & Chief Business Officer||7.7yrs||US$7.12m||0.0065% $12.9m|
|CFO & EVP of Global Supply & Business Operations||12.4yrs||US$7.14m||0.0061% $12.1m|
|Chief Scientific Officer and President of Worldwide Research||0.6yrs||US$7.07m||no data|
|Senior VP||0yrs||no data||0.0020% $4.0m|
|Executive VP and Chief Digital & Technology Officer||1.1yrs||no data||0.00078% $1.5m|
|Senior Vice President of Investor Relations||11.7yrs||no data||no data|
|Executive VP & General Counsel||6.2yrs||no data||0.0019% $3.7m|
|Executive VP and Chief Compliance||6.2yrs||no data||0.0012% $2.3m|
|Executive VP & Chief Development Officer||3.9yrs||no data||0.0016% $3.2m|
Experienced Management: PFE's management team is seasoned and experienced (6.2 years average tenure).
|Chairman of the Board & CEO||1.1yrs||US$9.85m||0.0051% $10.1m|
|Independent Director||23yrs||US$368.75k||no data|
|Lead Independent Director||2.1yrs||US$382.32k||no data|
|Independent Director||3yrs||US$363.39k||no data|
|Independent Director||12.4yrs||US$345.89k||0.000040% $79.1k|
|Independent Director||12.4yrs||US$363.39k||0.00018% $355.8k|
|Independent Director||5.7yrs||US$363.39k||0.000060% $118.6k|
|Member of Emerging Markets Advisory Board||0yrs||no data||no data|
|Independent Director||4.7yrs||US$353.75k||no data|
|Independent Director||8.2yrs||US$378.39k||no data|
Experienced Board: PFE's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PFE insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pfizer Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pfizer Inc.
- Ticker: PFE
- Exchange: NYSE
- Founded: 1849
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$197.679b
- Shares outstanding: 5.53b
- Website: https://www.pfizer.com
Number of Employees
- Pfizer Inc.
- 235 East 42nd Street
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PFE||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|PFE *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|0Q1N||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|PFE||OM (OMX Nordic Exchange Stockholm)||Yes||Common Stock||SE||SEK||Jan 1968|
|PFE||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|PFE||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1968|
|PFE||BVC (Bolsa de Valores de Colombia)||Yes||Common Stock||CO||COP||Jan 1968|
|PFES||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||SEK||Jan 1968|
|PFE||SNSE (Santiago Stock Exchange)||Yes||Common Stock||CL||USD||Jan 1968|
|PF-U||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|PFE||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|PFE||BVL (Bolsa de Valores de Lima)||Yes||Common Stock||PE||USD||Jan 1968|
|US_PFE_||KAS (Kazakhstan Stock Exchange)||Yes||Common Stock||KZ||KZT||Jan 1968|
|PFE||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 2 REP 1 ORD USD0.05||AR||ARS||Sep 2000|
|PFIZ34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR REPR 1 COM STK NPV||BR||BRL||May 2011|
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Oncolytics Biotech Inc.; licensing agreement with BionTech AG; strategic alliance with Verily Life Sciences LLC; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, Merck KGaA, Nektar Therapeutics, Syapse, Inc., eFFECTOR Therapeutics, Inc., and Insilico Medicine, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 01:09|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.